09:20 AM EST - InMed Pharmaceuticals Inc. : Announced it has launched B2B sales of the rare cannabinoid cannabidivarin to wholesalers, suppliers and end-product manufacturers in the health and wellness sector through its US subsidiary, BayMedica LLC. InMed Pharmaceuticals Inc.
shares N.INM are trading unchanged at $0.95.
